Frank Sirchia, MD
Family Medicine · Riverview, FLNPI 1467564252
Payments from drug & device makers
Across 175 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$386
- Amarin Pharma, Inc.$385
- Exact Sciences$383
- AstraZeneca$293
- Novo Nordisk$278
- Lilly USA, LLC$170
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,38898%
- Education$812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 25 | $386 |
| Amarin Pharma, Inc. | 9 | $385 |
| Exact Sciences | 18 | $383 |
| AstraZeneca | 20 | $293 |
| Novo Nordisk | 14 | $278 |
| Lilly USA, LLC | 9 | $170 |
| GSK | 7 | $150 |
| Amgen | 9 | $147 |
| Merck | 9 | $141 |
| Sanofi-aventis U.S. LLC | 7 | $119 |
| Boehringer Ingelheim | 5 | $99 |
| AbbVie(2 entities) | 5 | $89 |
| Astellas Pharma US Inc | 2 | $86 |
| Kowa Pharmaceuticals America, Inc. | 6 | $86 |
| Lucid Diagnostics Inc. | 3 | $71 |
| Esperion Therapeutics, Inc. | 3 | $58 |
| Novartis | 2 | $50 |
| Eisai Inc. | 2 | $47 |
| Medtronic | 2 | $43 |
| Boston Scientific | 2 | $39 |
| Johnson & Johnson | 2 | $36 |
| Itamar Medical Inc | 1 | $35 |
| Insmed, Inc. | 1 | $28 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Watermark Medical, Inc. | 1 | $23 |
| Si-bone, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Stryker | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Metuchen Pharmaceuticals | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$272
How this compares
$3,469 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $71,930 |
| JardianceEmpagliflozin | 32 | $42,400 |
| MounjaroTirzepatide | 31 | $33,284 |
| TrulicityDulaglutide | 23 | $31,419 |
| EliquisApixaban | 24 | $25,754 |
| FarxigaDapagliflozin Propanediol | 20 | $15,863 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,971 |
| VascepaIcosapent Ethyl | 12 | $11,992 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $9,632 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,415 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,347 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $6,515 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $3,858 |
| Omega-3 Acid Ethyl Esters | 16 | $1,831 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 20 | $1,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $278 | $71,93053 claims |
| Lilly USA, LLCMounjaro, Trulicity | $170 | $64,70354 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $99 | $52,03252 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $293 | $31,79342 claims |
| PfizerEliquis | $386 | $25,75424 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $150 | $22,31737 claims |
| AbbVieSynthroid | $89 | $88312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Riverview
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.